S&P 500, Eli Lilly and Company, Nomura Holdings Inc ADR, The Health Care Select Sector SPDR® Fund. Read 's Market Analysis on Investing.com ...

From the makers of Mounjaro, it's creating a stir on social media ...

When bad news drops, investors have a tendency to sell first and ask questions later. Let's take a closer look at why Viking ...

European stocks fell Thursday as investors weighed ongoing concerns about the artificial-intelligence boom and data showing gains in business activity. The composite purchasing managers' index for the ...

In people with recently diagnosed type 2 diabetes and no prior cardiovascular disease, self-reported physical activity ...

Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra ...

A rumor that pharmaceutical companies behind popular weight-loss and diabetes medications like Ozempic faced lawsuits totaling more than $2 billion circulated online in August 2025.

Sure, nobody goes around boasting, "We're Number Two!" But in certain circumstances, coming in second has its advantages.